Abstract | PURPOSE OF REVIEW: This review focuses on the recent developments in the field of drugs that affect HDL metabolism. Additionally, some general (retrospective) thoughts on fighting cardiovascular disease through modulating circulating lipids are discussed. RECENT FINDINGS: SUMMARY: Inhibition of cholesteryl ester transfer protein, antagomirs against microRNA-33, ApoA-I mimetics and PPARα or PPARα/δ agonists hold on the basis of the current data most promise. However, it will in our opinion be the key that patients with low HDL-c and increased triglyceride should be treated and not those at generally increased risk only. In the poststatin era, personalized medicine, which is inevitably on the horizon, is likely to be helpful for patients who do not reach the goals for LDL cholesterol and HDL-c according to the guidelines. Furthermore, functions of HDL will hopefully be identified as future pharmacological targets.
|
Authors | Jan-Willem Balder, Bart Staels, Jan A Kuivenhoven |
Journal | Current opinion in lipidology
(Curr Opin Lipidol)
Vol. 24
Issue 6
Pg. 500-9
(Dec 2013)
ISSN: 1473-6535 [Electronic] England |
PMID | 24184942
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Lipoproteins, HDL
- Cholesterol
|
Topics |
- Animals
- Biological Transport
(drug effects)
- Chemistry, Pharmaceutical
- Cholesterol
(metabolism)
- Humans
- Lipoproteins, HDL
(chemistry, metabolism)
- Pharmacology
(methods)
|